2020 PRODUCT CATALOGsemax sermorelin thymosin alpha 1 thymosin beta-4 pt-141 nasal spray (eros love spray) sexual wellness program for women sexual wellness program for men quad immune

PRODUCT CATALOGWELLS PHARMACY NETWORK

800-622-4510 [email protected] wellsrx.com800-622-4510 [email protected] wellsrx.com

2020

CONTENT

Wells Pharmacy Network is a privately held nationwide compounding pharmacy specializing in wellness, anti-aging, weight management, sexual wellness, aesthetic dermatology and thyroid and adrenal health.

Our mission is to elevate compounding industry standards through a unique combination of superior science and service. This includes operating a 21,000 503A pharmacy that meet the patients specifi c compounding needs and as well as a 4,000 SF FDA Registered 503B Outsourcing Facility that dispenses bulk medication for physician o� ce use.

Wells Pharmacy Network uses the most advanced instrumentation, including in-house sterility and endotoxin testing, which allow us to control the quality and timely delivery of our preparations, such as sterile implantable bioidentical hormone pellets and other custom medications. Patient safety is our priority and our commitment to the quality of the preparations we compound is the most important thing we do each and every day.

Learn more at: WELLSRX.COM

CONTENTA COMPOUNDING PHARMACY

DEDICATED TO QUALITY, SERVICE AND SAFETY.

ABOUT PELLETSSTERILE IMPLANTABLE HORMONE PELLETS

QUESTIONS503B LICENSING

LIST OF PRODUCTS

46

12

3

PELLETS

PRODUCTS

CONTENT

789101112131415161718

19202122

23

24

25

26

AOD 9604BPC-157CJC-1295/IPAMORELINDIHEXADSIPGHK-CUIBUTAMORENIPAMORELINKISSPEPTIN-10MELATONAN IIPEG-MGFPT-141(BREMELANOTIDE)SEMAXSERMORELINTHYMOSIN ALPHA 1 THYMOSIN BETA-4

PT-141 NASAL SPRAY(EROS LOVE SPRAY)SEXUAL WELLNESS PROGRAM FOR WOMENSEXUAL WELLNESS PROGRAM FOR MEN

QUAD IMMUNE

PRODUCTS SEXUAL WELLNESS

KITS

PEPTIDES

WELLSRX.COM

KRIS FISHMANPRESIDENT

CHRISTOPHER ULBRICHTVICE PRESIDENT OF OPERATIONS

MELISSA STEFKOVICE PRESIDENT OF QUALITY ASSURANCE

JUSTIN KIRKLANDVICE PRESIDENT OF PRODUCT DEVELOPMENT

HOWARD BROWN, R.PH PHARMACIST

TRACY JERNIGAN, PHARMDPHARMACIST

JOHN MUNGERVICE PRESIDENT OF ANALYTICS & PRICING

ANGIE ANDREWSDIRECTOR OF OPERATIONS

EDUARDO PANTOJAMARKETING DIRECTOR

JERRY GERMAINASSISTANT VICE PRESIDENT OF SALES

HEATHER VERMETTEASSISTANT VICE PRESIDENT OF SALES

ROBBY HAMMERSASSISTANT VICE PRESIDENT OF SALES

TANNER SUERVISE PRESIDENT OF SALES

SUSAN NELSON, CPHTCUSTOMER SERVICE MANAGER

[email protected]

PORTAL [email protected]

MANAGEMENTAND OPERATIONS TEAM

MARKETING AND SALES TEAM

CUSTOMER CARE TEAM

HAVE QUESTIONS?WE HAVE ANSWERS


PX3 PORTAL [email protected]

AK

800-622-4510 [email protected] wellsrx.com

AK

WELLS PHARMACY LICENSING

MD

DE

RI

NOT LICENSED

503A STATES LICENSED & PENDING 503B

503A & 503B STATES LICENSED

503B STATES LICENSED / NO 503A

AKHI

503A & 503B LICENSE STATUS

2

[email protected]

Weight ManagementThere are numerous factors that can a� ect weight loss, including hormonal issues. Wells o� ers a wide range of weight management solutions.

Aesthetic DermatologyA variety of pharmaceutical grade topicals to address common aesthetic issues and help your patients achieve a look they love.

Sexual HealthCustom compounded solutions to improve sexual function. Used in conjunction with erectile dysfunction, vaginal dryness, low libido, and other conditions

PeptidesMay improve hormonal balalnce and enhance energy, sleep quality, memory, sex drive and more by stimulation and release of hormones by the pituitary.

Thyroid & AdrenalThe thyroid produces hormones that a� ect metabolism which in turn impact energy, appetite, body temperature, heart rate, growth and more.

Sterile PelletsSterile pellets are used to treat hormone defi ciencies and imbalances. They are a small and cylindrical dosage form, about the size of a grain of rice, containing comprehensed bio-identical hormones.

BHRT (Bio-Identical Hormone Replacement Therapy)Hormones that are the same molecular structure and function as those produced in the human body. Our BHRT formulations range in a variety of options such as oral, topical, sterile, implantable or sublingual.

Corporate O� ce3420 Fairlane Farms Road, Ste. 300 Wellington, FL 33414

Ocala Pharmacy1210 SW 33rd AvenueOcala, FL 34474

Dyersburg Pharmacy 503B450 US Highway 51 BYP NDyersburg, TN 38024

Medication Questions or ConcernsQuality Hotline: 800-794-2360Email: [email protected]

3

WHY USE PELLETS?

3 ABOUT PELLETSARE BIOIDENTICAL HORMONE REPLACEMENT

PELLETS RIGHT FOR YOU?

WHAT ARE PELLETS?

WHAT ARE PELLETS USED FOR?

• Testosterone deficiencies• Erectile dysfunction• Urinary problems• Weight gain

• Menstrual headaches• Vaginal dryness• Incontinence• Migraines

• Low libido• Depression• Fatigue

Sterile pellets are a small, cylindrical form of compounded medication prepared using bioidentical hormones. They are used to treat hormone defi ciencies and imbalances in both men and women. The pellet is only about the size of a grain of rice and is implanted below the skin in the gluteal or abdominal area during a simple o� ce procedure. The area is numbed using a local anesthetic and a tiny incision is made through which the pellet is inserted using a trocar. Once it is in place, a sterile strip is used to close the incision and covered with an adhesive bandage. Over the course of three to four months, the pellet slowly dissolves as the body draws small, physiologic dosages of the hormone to maintain a more consistent delivery. Once it is dissolved, the procedure is repeated and a new pellet is inserted.


Pellets have been used as a safe, e� ective way to provide the body with hormones necessary for treatment of a wide variety of conditions. The doctor may prescribe sterile pellets for both men and women experiencing menopause or andropause, and with conditions such as:

One of the benefi ts of pellets is that pellets can be used to deliver hormones to the body that are both structurally and biologically identical to the body’s own hormones. Bioidentical hormones such as estradiol (E2) and testosterone are the most commonly used ingredients. They are slowly released over a period of three to four months, allowing for more consistent delivery. Because the pellet is placed beneath the skin, once it is inserted, the body naturally does the rest. Patients do not have to remember to take a pill, apply a cream, or give an injection. Patients also do not have to worry about getting the pellet removed because it is safely dissolved by the body over time. Once it is dissolved, the next pellet can be inserted by the physician.

* THE INFORMATION PROVIDED HERE IS FOR REFERENCE ONLY AND IS NOT TO BE RELIED UPON AS MAKING ANY REPRESENTATION AS TO THE EFFICACY OF ANY PARTICULAR FORMULATIONS. THE SAMPLE FORMULATIONS DESCRIBED HERE IN RESULT FROM PRESCRIPTIONS PREVIOUSLY ORDERED BY PROFESSIONALS LICENSED TO WRITE PRESCRIPTIONS IN THEIR RESPECTIVE DISCIPLINE. NOTHING HERE IS INTENDED TO REPLACE OR INFLUENCE THE INDEPENDENT JUDMENT OF ANY LICENSED PROFESSIONAL. ONLY YOUR PHYSICIAN CAN DETERMINE WHETHER A PARTICULAR FORMULATION IS RIGHT FOR YOU.


WHY USE PELLETS?

“This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.”

4

2ABOUT PELLETS

ARE BIOIDENTICAL HORMONE REPLACEMENT PELLETS RIGHT FOR YOU?

WHAT TO ASK YOUR DOCTOR ABOUT OUR PELLETS?

ARE PELLETS SAFE?

HOW ARE PELLETS MADE?

HOW CAN I BE SURE THAT PELLETS ARE RIGHT FOR ME?

WHAT IF I NEED THEM IMMEDIATELY?

Your doctor should look for pellets made in an FDA Registered 503B Outsourcing Facility to ensure the highest level of quality control. Also, fi nd out if the pharmacy is using only active ingredients made from USP grade materials and if the chemicals used purchased from FDA registered facilities.

For a more natural product, like the type that Wells Pharmacy specializes in, look for sterile implantable pellets that are created fusing together hormone powder and stearic acid without the use of chemical binders. These compressed pellets are about the size of a grain of rice and should be resistant to breakage and have a consistent color and texture for higher quality results that you and your doctor can be confi dent in.

Verify that your physician has access to a variety of strengths and compositions and that your doctor can prescribe the pellets for your specifi c needs. This further ensures that you are getting the proper dosage of each hormone for your condition. Confi rm that all orders are verifi ed once they are received for accuracy and completeness and go through extensive safety and sterility testing before leaving the facility. This will allow you to rest assured that the pellet you are receiving is compliant not only with high quality testing standards, but also prepared to meet your needs.

It can be hard to predict when you may need a prescription. To avoid delays in treatment, ensure your physician works with a company that o� ers overnight shipping for faster delivery of your medications.




To fi nd out more about how you could benefi t

from this specially compounded medication,

talk to your doctor today or visit the Wells

Pharmacy Network website:

wellsrx.com/sterile-pellets

Sterile implantable pellets are a safe, effective way to get the exact dosage of hormones your body needs for improved health and wellbeing.


7 5

WHAT TO ASK YOUR DOCTOR ABOUT OUR PELLETS?

STERILE IMPLANTABLE HORMONE PELLETS

F D A R E G I S T E R E D 5 0 3 B O U T S O U R C I N G F A C I L I T Y

OUR STERILE IMPLANTABLE HORMONE PELLETS

QUALITY & SAFETY• Highest quality and potency • Consistent color and texture• Resistant to breakage• Active ingredients made using USP grade materials derived from yam• Chemicals purchased from FDA registered facilities• PVP free• Irradiation sterilization via E-Beam sterilizes the pellet and the blister pack enclosure• Pellet dedicated pharmacists available to answer your questions

Wells Pharmacy Network now has an FDA Registered 503B Outsourcing Facility in Tennessee for the production of sterile implantable hormone pellets. The new “gold standard” for pellet production are in compliance with the FDA’s standards for CGMP (current good manufacturing practices), the same as large commercial drug manufacturers.


Bulk orders shipped to your office No minimum orders Faster turnaround time



EASY ORDERING

Call your Account Sales Team or email [email protected]

to place your order today.


5 6

4 AOD 9604ADVANCED OBESITY DRUG(MODIFIED PEPTIDE FRAGMENT OF HIGH)

DESCRIPTION

PROTOCOL

CLINICAL RESEARCH

AOD 9604 is a modifi ed form of amino acids 176-191 of the GH polypeptide.Investigators at Monash University discovered that the fat-reducing e� ects of GH appear to be controlled by a small region near one end of the GH molecule. This region, which consists of amino acids 176-191, is less than 10% of the total size of the GH Molecule and appears to have no e� ects on growth or insulin resistance.This hypothesis was proven in animals to a tremendous degree with specimen losing a signifi cant amount of fat mass. However, in phase three clinical trials the peptide didn’t mean its confi dence interval. Instead, it is now being studied for its e� ect on bone and cartilage.AOD 9604 possesses many other regenerative properties associated with growth hormone. Currently trials are underway to show the application of AOD 9604 in osteoarthritis, Hypercholesterolemia, bone and cartilage repair. AOD 9604 has an excellent safety profi le, recently obtaining Human GRAS status in the USA.

MOLECULAR FORMULA C78H123N23O23S2

MOLECULAR WEIGHT 18115.1

SEQUENCE Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-

Val-Glu-Gly-Ser-Cys-Gly-Phe

CONTENT & POTENCYINJECTABLE: 1200mcg/ml subcutaneous injectable provided in a 5ml vial.

SUGGESTED DOSAGEINJECTABLE: Inject 0.25ml subcutaneously once daily for 20 days.

Backgroud: The human growth hormone (hGH) has fat loss properties making it a potential candidate to treat obesity. AOD 9604 is a peptide fragment of theC-terminus of hGH (Tyr-hGH177-191), which harbors the fat reducing activity of hGH, without its negative effects. In this paper the safety data of AOD 9604 obtained in clinical trials are summarized.Methods: Six randomized, double-blind, placebo-controlled trials were performed with AOD 9604. Special focus was given to undesired effects associated with hGH treatment: increases in IGF-1 levels, insulin resistance, and impaired glucose tolerance. Blood samples were analyzed for presence of antiAOD 9604 antibodies to exclude immunogenicity.Results: AOD 9604 had no effect on serum IGF-1 levels, which confirms the hypothesis that AOD 9604 does not act via IGF-1. Results of oral glucose tolerance test demonstrated that, in contrast with hGH, AOD 9604 has no negative effect on carbohydrate metabolism. There were no anti-AOD 9604 antibodies detected in any of the patients selected for antibody assay. In none of the studies did a withdrawal or serious adverse event occur related to intake of AOD 9604.Conclusion: AOD 9604 displayed a very good safety and tolerability profile indistinguishable from placebo. AOD 9604 did not result in any of the adverse effects associated with full-length hGH treatment.

Safety and Tolerability of the Hexadecapeptide AOD 9604 in Humans Heike Stier, Evert Vos, David Kenley

DESCRIPTIONAOD 9604 is a modifi ed form of amino acids 176-191 of the

Investigators at Monash University discovered that the

DESCRIPTION



6 7

BPC-157P H Y S I C I A N E D U C A T I O N

BENEFITSWHAT IS BPC-157?

TYPICAL PRESCRIBING PROTOCOL:

• Accelerated wound healing

• Decreases inflamation

• Increased fibroblast

• Nitric oxide improvement

• Improves digestive function

• Enhanced vascular expression of VEGFR2

• Prescribing is often based on body weight using 2mcg/kg to as much as 10mcg/kg twice daily.

• Commonly used doses range from 200mcg to 400mcg twice daily (400mcg to 800mcg daily).

• If used twice daily, intramuscular injection as close to the injury as possible or via subcutaneously for systemic purposes.

• Use for 2-4 weeks before discontinuing; cease therapy for 2 weeks, then restart therapy if needed.

BPC-157 is a pentadecapeptide made up of 15 amino acids. It is a partial sequence of the body protection compound (BPC) derived from human gastric juice. Experiments have shown that it heightens the healing of many di� erent types of tissues, including: tendon, muscle, nervous system, and is superior at healing damaged ligaments.Patients who su� er from discomfort due to sprains, tears, and tissue damage may benefi t from treatment with this peptide as it can increase blood fl ow back to the injured sites. BPC-157 may protect organs, prevent stomach ulcers, and heal skin burns.


REFERENCE: CHANG, CH, ET AL. “THE PROMOTING EFFECT OF PENTADECAPEPTIDE BPC 157 ON TENDON HEALING INVOLVES TENDON OUTGROWTH, CELL SURVIVAL, AND CELL MIGRATION.” HTTPS://WWW.NCBI.NLM.NIH.GOV/PUBMED/21030672, 11 MAR. 2011, WWW.NCBI.NLM.NIH.GOV/PUBMED/21030672.

* THE INFORMATION PROVIDED HERE IS FOR REFERENCE ONLY AND IS NOT TO BE RELIED UPON AS MAKING ANY REPRESENTATION AS TO THE EFFICACY OF ANY PARTICULAR FORMULATIONS. THE SAMPLE FORMULATIONS DESCRIBED HERE IN RESULT FROM PRESCRIPTIONS PREVIOUSLY ORDERED BY PROFESSIONALS LICENSED TO WRITE PRESCRIPTIONS IN THEIR RESPECTIVE DISCIPLINE. NOTHING HERE IS INTENDED TO REPLACE OR INFLUENCE THE INDEPENDENT JUDMENT OF ANY LICENSED PROFESSIONAL.


Patient benefi ts over time may include:


7 8

6CJC-1295/IPAMORELINP H Y S I C I A N E D U C A T I O N

BENEFITS

WHAT IS CJC-1295?

WHAT IS IPAMORELIN?HOW IS IT USED WITH CJC-1295?

TYPICAL PRESCRIBING PROTOCOL:

RECOMMENDED TREATMENT PLANS BASED ON EACH VIAL LASTING 30 DAYS:

• Promotes slow wave sleep

• Improves memory retention

• Stimulates muscle growth

• Aids in fat loss & lean muscle

• Benefi ts can be seeing using as little as 100mcg of each CJC-1295/Ipamorelin.• Injections can be done before bed or TID.• Recommended to take at least 30 minutes away from food.• Patients with a higher BMI or high estrogen levels may require larger doses.

30 doses 0.07cc (7 units) subcutaneous provides 133mcg/133mcg per injection

20 doses 0.10cc (10 units) subcutaneous provides 200mcg/200mcg per injection

40 doses 0.05 cc (5 units) subcutaneous provides 100mcg/100mcg per injection (AM + PM)

CJC-1295 is a tetrasubstituted 29-amino acid Growth Hormone Releasing Hormone (GHRH) analog. It stimulates a release of HGH and IGF-1 without raising prolactin levels, leading to fat loss and increased protein synthesis thereby promoting growth of muscle. Our CJC-1295 is compounded without DAC (Drug A� nity Complex) which provides a more e� ective GH spike resembling a normal physiologic release of GH.

Ipamorelin Acetate is a Growth Hormone Releasing Peptide (GHRP) that assists increasing the amount of growth hormone released. Ipamorelin is a pentapeptide composed of fi ve amino acids and has a biological half-life of 2 hours after administration. It is widely known for being able to suppress somatostatin or Growth Hormone Inhibiting Hormone (GHIH). Using CJC-1295 in conjunction with Ipamorelin may be more e� ective in the production of growth hormone secretion, and in helping speed recovery time after an injury.





A B C


9

BENEFITS

RECOMMENDED TREATMENT PLANS BASED ON EACH VIAL LASTING 30 DAYS:

• Promotes slow wave sleep

• Improves memory retention

• Stimulates muscle growth

• Aids in fat loss & lean muscle

DIHEXA

DESCRIPTION

PROTOCOL

CLINICAL RESEARCH

DIHEXA is a peptide variant derived from angiotensin IV. Clinical studies suggest that DIHEXA improves cognitive function as shown in animal models of disease such as Alzheimer’s. Angiotensin IV is a derivative of the vasoconstrictor angiotensin II which has been shown in animal studies to enhance acquisition, consolidation and recall of learning and memory when administered centrally or peripherally. In an assay of neurotrophic activity, DIHEXA was found to be seven orders of magnitude more potent than brain-derived neurotrophic factor and is thought may be able to help in the repair of the brain and nerves in neurological disease.

MOLECULAR FORMULA C27H44N4O5

MOLECULAR WEIGHT 504.672 g/mol

CHEMICAL NAME N-hexanoic-Tyr-Ile-(6)

aminohexanoic amide

CONTENT & POTENCYCREAM: 20 mg/mL transdermal cream provided in a 30 mL applicator.CAPSULE: 10 mg and 20 mg oral capsule.

SUGGESTED DOSAGECREAM: Apply 0.5-1 mL (2-4 clicks) to inner forearm daily, rub in until absorbed.CAPSULE: Take 1 capsule by mouth daily.

A subset of angiotensin IV (AngIV)–related molecules are known to possess procognitive/antidementia properties and have been considered as templates for potential therapeutics. However, this potential has not been realized because of two factors: 1) a lack of blood-brain barrier–penetrant analogs, and 2) the absence of a validated mechanism of action. The pharmacokinetic barrier has recently been overcome with the synthesis of the orally active, blood-brain barrier–permeable analog N-hexanoic-tyrosine-isoleucine-(6) aminohexanoic amide (dihexa). Therefore, the goal of this study was to elucidate the mechanism that underlies dihexa’s procognitive activity. Here, we demonstrate that dihexa binds with high affinity to hepatocyte growth factor (HGF) and both dihexa and its parent compound Norleucine 1-AngIV (Nle1-AngIV) induce c-Met phosphorylation in the presence of subthreshold concentrations of HGF and augment HGF-dependent cell scattering. Further, dihexa and Nle1-AngIV induce hippocampal spinogenesis and synaptogenesis similar to HGF itself. These actions were inhibited by an HGF antagonist and a short hairpin RNA directed at c-Met. Most importantly, the procognitive/antidementia capacity of orally delivered dihexa was blocked by an HGF antagonist delivered intracerebroventricularly as measured using the Morris water maze task of spatial learning.

Benoist CC, Kawas LH, Zhu M, et. al. The Procognitive and Synaptogenic e� ects of Angiotensin IV-Derived Peptides are Dependent on Activation of the Hepatocyte Growth Factor/c-Met System. J. Pharmacol Exp Ther. 2014 Nov;351(2):390-402. doi: 10.1124/jpet. 114.218735. Epub 2014 Sep 3



9 10

8 DSIPDELTA SLEEP INDUCING PEPTIDE

DESCRIPTION

PROTOCOL

CLINICAL RESEARCH

DSIP is a naturally occuring somnogenic nonapeptide with possible physiological functions impacting neuromodulation. DSIP is typically found in the brain and easily passes the blood-brain barrier.Studies indicate that DSIP and its analogues are best classified as peptide neuromodulators. DSIP has been shown to exhibit a pronounced stress protective action and demonstrated a decrease in stress-induced metabolic disorders in both human and animal models. It is believed that DSIP works by modulating activity of GABAergic, glutamatergic, and other neuronal systems.



SEQUENCE Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu

CONTENT & POTENCY1 mg/mL subcutaneous injection provided in a 3 mL vial.

SUGGESTED DOSAGEInject 0.1 mL subcutaneously once daily at bedtime.

In several species DSIP at low doses has been shown to promote sleep. Although its physiological role remains to be clarifi ed, DSIP illustrates several concepts applicable to other brain peptides. These include the bell-shaped dose-response curve, central e� ects after peripheral administration, a delayed and prolonged time course, and some penetration of the blood-brain barrier in essentially intact form. Concepts applicable to one neuropeptide, therefore, appear to be applicable to others. In this article Abba Kastin and colleagues review the known e� ects of DSIP and argue that more work needs to be carried out before it can be labelled functionally.

Miller LH, Turnbull BA, Kastin AJ, et. al. Sleep-Wave Activity of a Delta Sleep-Inducing Peptide Analog Correlates with its Penetrance of the Blood-Brain Barrier. Sleep. 1986;9(1):80-4



1 11

DESCRIPTION

PROTOCOL

CLINICAL RESEARCH

GHK-Cu is a naturally occurring copper complex that was fi rst identifi ed in human plasma, but has since been found in multiple locations such as saliva and urine. Copper peptides are small, naturally occurring protein fragments that have high a� nity for copper ions, which evidence suggests are critical to normal body function. Clinical studies indicate that GHK-Cu has a variety of roles in the human body including, but not limited to, promoting activation of wound healing, attracting immune cells, antioxidant and anti-infl ammatory e� ects, stimulating collagen and glycosaminoglycan synthesis in skin fi broblasts, and promoting blood vessel growth. There has been some clinical evidence that has shown that GHK-Cu acts as a feedback signal generated after tissue injury and it may act as a potent protector of tissue and anti-infl ammatory agent possibly by reducing the oxidative damage that occurs post-tissue injury. Further, GHK-Cu has been found to be involved in signaling tissue remodeling by removing damaged/scarred tissue and generating healthy tissue. It has been shown in studies that GHK concentration decreases with age because the concentration of GHK-Cu in the body decreases with age which may result is an increase in infl ammation, cancerous activity, and tissue destruction.

MOLECULAR FORMULA C28H52CuN12O8


SEQUENCE Gly-His-Lys(cu2+)

CONTENT & POTENCYINJECTABLE: 10 mg/mL subcutaneous injection provided in a 5 mL vial.TRANSDERMAL (SCALP): 5 mg/mL (0.5%) topical foam provided in a 50 mL foaming applicator.TRANSDERMAL (FACIAL): 5 mg/mL (0.5%) facial cream provided in a 15 gm pump.

SUGGESTED DOSAGEINJECTABLE: Inject 0.2 mL subcutaneously once daily.TRANSDERMAL (SCALP): Apply 2-3 pumps to scalp once daily at night.TRANSDERMAL (FACIAL): Apply 1-2 pumps to face and rub in at night.

GHK (glycyl-L-histidyl-L-lysine) is present in human plasma, saliva, and urine but declines with age. It is proposed that GHK functions as a complex with copper 2+ which accelerates wound healing and skin repair. GHK stimulates both synthesis and breakdown of collagen and glycosaminoglycans and modulates the activity of both metalloproteinases and their inhibitors. It stimulates collagen, dermatan sulfate, chondroitin sulfate, and the small proteoglycan, decorin. It also restores replicative vitality to fibroblasts after radiation therapy. The molecule attracts immune and endothelial cells to the site of an injury. It accelerates wound-healing of the skin, hair follicles, gastrointestinal tract, boney tissue, and foot pads of dogs. It also induces systemic wound healing in rats, mice, and pigs. In cosmetic products, it has been found to tighten loose skin and improve elasticity, skin density, and firmness, reduce fine lines and wrinkles, reduce photodamage, and hyperpigmentation, and increase keratinocyte proliferation. GHK has been proposed as a therapeutic agent for skin inflammation, chronic obstructive pulmonary disease, and metastatic colon cancer. It is capable of up- and downregulating at least 4,000 human genes, essentially resetting DNA to a healthier state. The present review revisits GHK’s role in skin regeneration in the light of recent discoveries.

Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. Biomed Res Int 2015;2015:648108. doi: 10.1155/2015/648108. Epub 2015 Jul 7.

DESCRIPTIONGHK-Cu is a naturally occurring copper complex that was fi rst identifi ed in human plasma, but has since been found in multiple locations such as saliva and urine. Copper

DESCRIPTION



11 12GHK-CuCOLLAGEN & AESTHETIC PEPTIDE

IBUTAMOREN MESYLATEP H Y S I C I A N E D U C A T I O N

BENEFITSWHAT IS IBUTAMORENMESYLATE

TYPICAL PRESCRIBING PROTOCOLS:

• Increase muscle mass• Decrease fat mass• Faster healing• Firmer healthier skin• Healthier hair• Improved quality sleep• Combats aging

• Ibutamoren is available as a 10 mg or 25 mg oral tablet. As opposed to some of our other sublingual tablets, it is intended to be swallowed. The tablet can be split in order to deliver a lower dose for a specifi c patient and is commonly prescribed at bedtime once daily.

• The Ibutamoren clinical studies were conducted over short durations of up to 8 weeks. Therefore, taking an initial IGF-1 baseline and then taking periodic blood tests early on during therapy is suggested.

• Reach out to your Account Representative today to get more information on Ibutamoren or to place an order. If you don’t know who to contact, call 800.622.4510, or email [email protected]

Ibutamoren is classifi ed as a non-peptide growth hormone secretagogue and mimics the growth hormone stimulating action of ghrelin. Ibutamoren is considered to be potent, long-acting, and available through oral administration. Clinically, it has been demonstrated to increase endogenous release of growth hormone (GH) as well as insulin-like growth factor 1 (IGF-1) without the adverse increase of prolactin or cortisol often seen with GHRPs. Additionally, increases in lean body mass can be achieved while lowering LDL cholesterol. Studies have shown Ibutamoren stimulates brain regions involved with metabolic action, such as the hypothalamus and the pituitary. Ibutamoren may be e� ective in increasing both muscle mass and bone mineral density, making it a promising therapy for the treatment of frailty and osteoporosis in the elderly.






7 13

IPAMORELINP H Y S I C I A N E D U C A T I O N

BENEFITSWHAT IS IPAMORELIN ACETATE?

WHY WOULD I WANT TO USE IPAMORELIN?

WHAT STRENGTHS & FORMS ARE AVAILABLE? WHAT YOU NEED TO KNOW?

• Aid in the body’s ability to burn fat

• Helps improve lean muscle mass

• Supports immune system

• Improved sex drive

• Strengthened cardiovascular system

• Improved quality of sleep

• Improved energy and endurance

• Supports bone density

• Improved skin fi rmness and moisture retention

• Improved cognition and memory

Reach out to your Account Representative today to get more information on Ipamorelin or to place an order. If you don’t know who to contact, call 800.622.4510, or email [email protected]

Discuss with your physician to see if Ipamorelin would be right for you. Ipamorelin injectable therapy can only be used under a physicians care. With Ipamorelin therapy, you may notice improved recovery after workouts and better quality of sleep. Always inform your physician about changes in medications and supplements. Common side e� ects, as with any injectable medication, may include injection site reaction such as pain at the injection site.

Ipamorelin Acetate is a Growth Hormone Releasing Peptide (GHRP) that stimulates the pituitary gland within the body to release natural growth hormone (GH). Ipamorelin Acetate is a pentapeptide composed of fi ve amino acids and has a biological half-life of 2 hours after administration. It is widely known for being able to suppress somatostatin or growth inhibiting hormone.As we age, our hormone levels fl uctuate interfering with patient’s overall quality of life. Imbalances can result in loss of energy, increased irritability, sleeplessness, memory problems, and low sex drive. Utilizing peptide therapy separately or in conjunction with hormone replacement may restore optimal hormone levels in your patients. Studies suggest that Ipamorelin Acetate did not a� ect FSH, LH, Prolactin, or TSH levels. Furthermore, Ipamorelin did not seem to have an impact on cortisol and ACTH levels during GHRH stimulation.

With age, our hormone levels fl uctuate and often decline interfering with a patient’s overall quality of life. Imbalances can result in loss of energy, increased irritability, sleeplessness, memory problems, and low sex drive. Utilizing peptide therapy separately or in conjunction with hormone replacement may restore optimal hormone levels in your patients. Studies suggest that Ipamorelin Acetate does not clinically a� ect FSH, LH, Prolactin, or TSH levels. Furthermore, Ipamorelin did not seem to have a clinically adverse impact on cortisol or ACTH levels.


REFERENCE: HTTPS://WWW.NCBI.NLM.NIH.GOV/PUBMED/9849822





1413

1515KISSPEPTIN-10 DESCRIPTION

PROTOCOL

CLINICAL RESEARCH

Kisspeptin-10 is an endogenous neuropeptide product of the KISS1 gene. It acts as a modulator of the Hypothalamus-Pituitary-Gonad Axis (HPG). This peptide stimulates the secretion of gonadotrophin-releasing hormone (GnRH) at an upstream position. Animal and human studies show an increase in luteinizing hormone and follicle-stimulating hormone post Kisspeptin-10 administration. Kisspeptin performs this function by directly sending signals to GnRH neurons.

Kisspeptin may be a benefi cial addition to a Testosterone Replacement Therapy (TRT) program. With TRT therapy, higher levels of testosterone act on the pituitary through the Hypothalamic-Pituitary-Gonadal Axis negative feedback loop to inhibit the release of GnRH and correspondingly reduce the pulse frequency of Luteinizing Hormone. Without the presence of LH, the testicles will cease producing testosterone, defi ned as hypogonadism, which can lead to a reduction in testicle size. Kisspeptin is used to counteract the reduced LH pulse frequency by increasing the frequency of the GnRH pulse. Additionally, stimulation to the Leydig cells can occur resulting in an increase in testosterone production.



CHEMICAL NAME Try-Asn-Trp-Asn-Ser-Phe-

Gly-Leu-Arg-Phe-NH2

CONTENT & POTENCYEach 2ml sterile vial of Kisspeptin-10 contains 2mg of Kisspeptin-10.

SUGGESTED DOSAGEInject 0.1ml subcutaneously twice weekly.

The HPG axis is controlled by a negative feedback loop. In the healthy brain, the hypothalamus releases gonadotropin-releasing hormone (GnRH) into the median eminence, and then GnRH is transported via the hypophyseal portal system to the anterior pituitary where it acts on its receptor (GnRHR). Signaling from GnRHR leads to the production and secretion of the gonadotropins, including luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Once the gonadotropins are secreted into the bloodstream, LH acts on its receptor in the gonads, which in turn stimulates the release of the sex steroids, androgens, and estrogens. These sex steroids complete a negative feedback loop by inhibiting the release of GnRH.

Kisspeptin-10 can possibly be used as an alternative to HCG in male patients with testicular atrophy with dosing optimized by measuring FSH and LH via blood work. Recommended dosing for use in conjunction with Testosterone Replacement Therapy to maintain fertility and deter against testicular atrophy is 2-3 times per week at 0.1ml−0.2ml per injection from a 1mg/ml sterile vial. Dosing can be adjusted linearly if using as a substitute for HCG. LabCorp reference values for adult males for FSH are at 1.5−12.4 (mIU/mL) and 1.7−8.6 (mIU/mL) for LH.

Dosing should be monitored by regular blood work measuring Luteinizing Hormone and Follicle Stimulating Hormone.

FRONT ENDOCRINOL (LAUSANNE). 2015; 6:45 DOI:10.3389/FENDO.2015.00045

Prolonged use has not been evaluated. Administration of multiple doses daily has been associated with tachyphylaxis.


15

DESCRIPTIONKisspeptin-10 is an endogenous neuropeptide product of the KISS1 gene. It acts as a modulator of the Hypothalamus-Pituitary-Gonad Axis

15

DESCRIPTION


MELANOTAN IITANNING AND FAT LOSS

DESCRIPTION

PROTOCOL

CLINICAL RESEARCH

Melanotan I and Melanotan II are both analogs of the peptide hormone alphamelanocyte stimulating hormone (a-MSH) that induces skin tanning. Like its predecessor, Melanotan I, MT 2 plays a role in stimulating melanogenesis and thus provides a protective mechanism against UV rays since under its actions melanocytes are able to increase production and secretion of the hormone melanin. Scientists have also noticed that MT 2 had a positive e� ect on libido due to its aphrodisiac properties. Additionally, MT 2 exhibits a mild positive fat-mobilizing e� ect. Melanotan I is an FDA approved drug under the brand name Scenesse. Scenesse is most commonly used to treat patients that have an intolerance to light.



SEQUENCE Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-

NH2(cyclic 2-7)

CONTENT & POTENCYINJECTABLE: 5ml at 2000mcg/ml : ready-to- inject subcutaneously

SUGGESTED DOSAGEINJECTABLE: 0.15ml daily for 1 - 2 weeks then 0.25mL twice weekly for maintenance.

Abstract: A pilot phase I study was conducted with a cyclic heptapeptide analog of alpha-melanocyte stimulating hormone (alpha-MSH). The lactam-bridged molecule, called Melanotan-II (MT-II), has the structure Ac-Nle4-Asp5-His6-D-Phe7-Arg8-Trp9- Lys10 alpha-MSH4-10-NH2 (MT-II) and has superpotent melanotropic activity in vitro. A single-blind, alternating day (saline or MT-II), placebo-controlled trial was conducted in 3 normal male volunteers at the starting dose of 0.01 mg/kg of MT-II. Subcutaneous injections of MT-II or saline were given daily (Monday-Friday) for 2 consecutive weeks. Two subjects wereescalated by 0.005 mg/kg increments to 0.03 mg/kg and one to 0.025 mg/kg. The 0.03 mg/kg dose produced Grade II somnolence and fatigue in one of two subjects (WHO standards). Mild nausea, not requiring antiemetic treatment, was reported at most MT-II dose levels. A stretching and yawning complex appeared to correlate with the onset of spontaneous, Penile erections which were intermittently experienced for 1-5 hours after MT-II dosing, depending on the MT-II dose. Two subjects had increased pigmentation in the face, upper body and buttock, as measured by quantitative reflectance and by visual perception 1 week after MT-II dosing ended. These results demonstrate that MT-II has tanning activity in humans given only 5 low doese every other day by subcutaneous injection. The recommended single MTII dose for future Phase I studies is 0.025 mg/kg/day.

Dorr RT, Lines R, Levine N, Brooks C, Xiang L, Hruby VJ, Hadley ME. Source: College of Medicine, Pharmacology Department, University of Arizona, Tucson, USA.

DESCRIPTIONMelanotan I and Melanotan II are both analogs of

DESCRIPTION



15 16

17PEG-MGFMECHANO GROWTH FACTOR

PROTOCOL


MOLECULAR WEIGHT 4867

SEQUENCE Tyr-Gln-Pro-Pro-Ser-Thr-Asn-Lys-

Asn-Thr-Lys-Ser-Gln-Arg-Arg-Lys-Gly-Ser-Thr-

Phe-Glu-Glu-Arg-Lys

CONTENT & POTENCY2 mg/mL subcutaneous injection provided in a 5 mL vial.

SUGGESTED DOSAGEInject 0.1 mL subcutaneously once daily 5 out of 7 days of the week.



CLINICAL RESEARCH

Abstract: Di� erent insulin-like growth factor-1 (IGF-1) isoforms, namely IGF-1Eb and IGF-1Ec (MGF),have been proposed to have various functions in muscle repair and growth. To gain insight into the potentially di� erential actions of IGF-1 isoforms in the regulation of muscle regeneration, we assessed the time course of their expressions at both mRNA and protein levels after exercise-induced muscle damage in humans. In addition, we characterized mature IGF-1 and synthetic MGF E peptide signalling in C2C12 myoblast-like cells in vitro. Ten healthy male volunteers were subjected to exercise-induced muscle damage and biopsy samples were taken from the exercised muscles before and 6 h, 2,5 and 16 days post exercise. Muscle damage was documented by specifi c functional and biochemical responses post exercise. PCR-based analyses of muscle biopsy samples revealed a rapid and transient up-regulation of MGF mRNA expression which was followed by a prolonged increase of IGF-1Ea and IGF-1Eb mRNA expression (p<0.05). Patterns similar to those for mRNA expression were detected for MGF and IGF-1Ea expression at the protein level. The action of synthetic MGF E peptide di� ered from that of mature IGF1 since its proliferative e� ect on C2C12 myoblast-like cells was not blocked by an anti-IGF-1 receptor neutralizing antibody and it did not phosphorylate Akt. Therefore, we conclude that the di� erential expression profi le of IGF-1 isoforms in vivo and the possible IGF-1R- independent MGF E peptide signaling in skeletal muscle-like cells in vitro support the notion that tissue-specifi c mRNA expression of MGF isoform produces mature IGF-1 and MGF E peptides which possibly act as distinct mitogens in skeletal muscle regeneration.

Philippou A, Papageorgiou E, Bogdanis G. et. al. Expression of IGF-1 isoforms after exercise-induced muscle damage in humans: characterization of the MGF E peptide actions in vitro. In Vivo 2009 Jul-Aug;23(4):567-75.

DESCRIPTIONMGF is a split variant of IGF-1 and differs from the systemically produced IGF-1. It is believed that IGF-I is spliced towards MGF thereby possibly initiating muscle hypertrophy and repair of local damage. Studies show that MGF is expressed by mechanically overloaded muscle and may be involved in tissue repair and adaptation. MGF is PEGylated, in order to increase the half-life.

PT-141P H Y S I C I A N E D U C A T I O N

BENEFITSWHAT IS PT-141?

SIDE EFFECTS

TYPICAL PRESCRIBING PROTOCOL:MALE:

FEMALE:

• Improves female sexual arousal disorder

• Improve sexual function in men (such as erectile dysfunction or impotence)

• Nausea • Flushing • Headache

• Males with no history of ED may begin with 1mg (0.1mL) via subcutaneous injection in the lower right quadrant of abdomen at least 45 minutes prior to sexual activity (titrating dose upward to e� ect as needed or tolerated).

• Males with a history or diagnosis of ED with inadequate response to Sildenafi l 100mg may begin with 4mg (0.4mL) via subcutaneous injection in the lower right quadrant of abdomen approximately 45 minutes prior to sexual activity (titrating dose upward to e� ects as needed or tolerated).

• Females with FSAD or HSDD may begin with 750mcg - 1mg (0.075mL - 0.1mL) via subcutaneous injection (titrating dose upward to e� ect as needed or tolerated) at least 45 minutes prior to sexual activity. Recommended to use no more than two times per week.

PT-141 was developed from the peptide Melanotan 2, which is a synthetically produced variant of a peptide hormone naturally produced in the body that stimulates melanogenesis that is known as alpha- Melanocyte stimulating hormone. PT-141 has been shown in studies to provide libido-enhancing e� ects by activating the melanocortin receptors MC1R and MC4R, without tanning the skin.PT-141 is a potential remedy for the treatment of female sexual dysfunction and male erectile dysfunction. Studies have shown that PT-141 does not act on the vascular system, but may increase sexual desire through the nervous system.


REFERENCE: SHADIACK, AM, ET AL. “MELANOCORTINS IN THE TREATMENT OF MALE AND FEMALE SEXUAL DYSFUNCTION.” PUBMED.GOV, 2007, WWW.NCBI.NLM.NIH.GOV/PUBMED/17584134.




Side e� ects for males and females may include:


1817

1919SEMAXNEUROPEPTIDE

DESCRIPTION

PROTOCOL

CLINICAL RESEARCH

Heptapeptide SEMAX (MEHFPGP) is the analogue of ACTH (4-10) that has a demonstrated prolonged neurotropic activity. This has historically been used in patients with pathologies related to brain circulation dysfunction. It has also been suggested in literature that due to its e� ect on carboxypeptidase it may also increase physical performance and adaptation capacities in exposure to high intensity exercise and at higher doses, >0.5 mg/kg, may exhibit analgesic like e� ects.Often prescribed for: Anti-Thrombosis,

ADHD/Learning, Gastric protection, Physical exertion improvement pain, Metal toxicities.

MOLECULAR FORMULA C37H51N9O10S


SEQUENCE Met-Glu-His-Phe-Pro-Gly-Pro

CONTENT & POTENCY1 mg/mL subcutaneous injection provided in a 5 mL Vial.

SUGGESTED DOSAGEInject 0.3-1 mL subcutaneously twice per week, depending on patient response.

The heptapeptide Semax (MEHFPGP) is an analog of the fragment ACTH(4–10) with long-lasting actions.The aim of the present work was to study the effects of Semax on learning ability and pain sensitivity in white rats given different doses via the intraperitoneal and intranasal routes. The nootropic effects of Semax were studied in a test based on the acquisition of a conditioned passive avoidance reaction to pain stimulation. Pain sensitivity was assessed in a hindpaw compression test. The results showed that i.p. Semax had nootropic and analgesic actions. Dose-response characteristics were different for these different effects. Intranasal Semax was more effective in improving learning in animals than i.p. Semax but had no effect on pain sensitivity. Our results provide evidence that different mechanisms and brain structures are involved in mediating the nootropic and analgesic effects of Semax.

Manchenko DM, Glazova Nlu, Levitskaia NG, et. al. Nootropic and Analgesic Effects of Semax Following Different Routes of Administration. Ross Fiziol Zh Im I M Sechenova. 2010 Oct; 96(10):1014-23.

1919



SERMORELINP H Y S I C I A N F A Q s

HOW TO RECONSTITUTELYOPHILIZED VIALS

CAN I DOSE BY WEIGHT OR BMI?

SIDE EFFECTS

WHAT IS THE MINIMUM AMOUNT OF TIME A PATIENT SHOULD TAKE BEFORE THEY SEE RESULTS?

WHAT IF MY PATIENT DID NOT SEE A CHANGE THEY HOPED FOR?

WHAT IS INCLUDED WITH THE SHIPMENT?

WILL MY PATIENTS EXPERIENCE HUNGER?

POSSIBLE OVERDOSE?

IS THIS PRODUCT FDA APPROVED?

HALF-LIFE?

THE IGF-1 LABS DID NOT CHANGE?

PATIENTS ON PREVIOUSLY ON HUMAN GROWTH HORMONE WILL THIS WORK?

BMI MEN WOMEN

• Vial of medication• Vial of diluent• MIxing syringe with an attached needle• #2 alcohol pads for mixing purposes

We recommend the following for any size vial to calculate a 30 day supply:

• 6mg Vial with 6mL reconstitution; (0.2mL=200mcg) & (0.3mL=300mcg)



*Make sure that your patient knows that a sterile multi-use vial should be discarded after 28-30 days.

If dosing based on BMI, this requires adjustments for male/female patients due to the blunting e� ect estrogren has on GH/IGF-1 production. Also, BMI should not be totally relied upon for dosing as BMI does not take into account lean muscle mass. The patient’s overall health and fi tness status should be considered rather than dosing based on a number value from a patient’s weight and height alone.

Most common is injection site reaction (pain; redness; swelling). Less than 1% dizziness, fl ushing, headache or hyperactivity.

Most patients will begin to feel sleep changes in the fi rst week. For best results patients should commit to using for 90 days to feel the full benefi ts.

Just as with BHRT therapy changes in the body are measured in both the labs and in the feedback from your patients. It’s important to discuss both as well as their expectations.

18-2425-29

200mcg400mcg

300mcg400-500mcg


In each shipment from Wells Pharmacy, the patient will be provided the following for each kit ordered:

It can be caused for some by the stimulation of ghrelin for a small percentage of patients using GHRP-6.

No, due to the saturation e� ect. This therapy has also been shown to help to rebuild and preserve pituitary function for many patients.

Sermorelin was FDA approved in 1997 to treat GH defi ciency, in 2002 Geref from Serono was discontinued in part due to the high cost. The chemicals purchased by Wells Pharmacy are from FDA approved facilities and vendors.

Sermorelin has a half-life of 11-12 minutes following subcutaneous administration *Per original package insert.

The feedback from the patient on how they are feeling is equally important as the lab testing. Remember, that you are treating a patient and not a number. In some patients the dosage may need to be titrated up or converted to a blend of all 3 (GHRH/GHRP-2/GHRP-6) to experience results. (It is important that the labs are measured at the same time every time).

Yes, however in some rare cases Sermorelin therapy will not work if somatostatin has inhibited all GH production. High levels of GH can cause an increase in somatostatin via the feedback look and decrease GH production. Because GHRP inhabits somatostatin, the addition of GHRP to Sermorelin will assist in decreasing somatostatin; thereby, increasing the number of somatotrophs and subsequently increase somatropin and GH production to a larger extent than using Sermorelin alone.

*All supplies for injections are sold separately


2019

THYMOSIN ALPHA 1

DESCRIPTION

PROTOCOL

CLINICAL RESEARCH

Thymosin Alpha 1 (TA1) is a peptide originally isolated from thymic tissue and is a compound believed to be responsible for restoring immune function in thymectomized mice. Thymosin Alpha 1 has been shown to have a pleiotropic mechanism of action and a� ects multiple immune cell subsets that are involved in immune suppression. Studies have demonstrated improvements in immune system cell subsets and the potential of TA1 for the treatment of a range of diseases. Thus, Thymosin Alpha 1, due to the immune stimulating e� ects exhibited by TA1, may have utility for the treatment of age or disease related immune suppression.



SEQUENCE Ac-Ser-Asp-Ala-Ala--Val-Asp-Thr-Ser-Ser-Glu-

Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-

Ala-Glu-Asn-OH

CONTENT & POTENCYINJECTION: 3000 mcg/mL subcutaneous injection provided in a 5 mL vial.

SUGGESTED DOSAGEINJECTION: Inject 0.15 mL subcutaneously daily

Thymosin A1 (TA1), a thymosin-related 28-mer synthetic amino-terminal acetylated peptide, has gained increasing interest in recent years, due to its pleiotropy. The peptide has been used worldwide as an adjuvant or immunotherapeutic agent to treat disparate human diseases, including viral infections, immunodefi ciencies, and malignancies. The peptide can enhance T cell, dendritic cell (DC), and antibody responses, modulate cytokine and chemokine production, and block steroid-induced apoptosis of thymocytes. Its central role in modulating DC function and activating multiple signaling pathways that contribute to di� erent functions may o� er a plausible explanation for its pleiotropic action. Additionally, the ability of TA1 to activate the indoleamine 2,3-dioxygenase enzyme—which confers immune tolerance during transplantation and restrains the vicious circle of chronic infl ammation—has been a turning point, suggesting a potential, specifi c function in immunity. Accordingly, TA1 has recently been shown to promote immune reconstitution and improve survival of recipients of HLA-matched sibling T cell–depleted stem cell transplants in a phase I/II clinical trial. Thus, TA1 continues to live up to its promises.


King R, Tuthill C. Immune Modulation with Thymosin Alpha 1 Treatment. Vitam Horm. 2016; 102:151-78. doi: 10.1016/bs.vh. April 3, 2016. Epub May 24, 2016.


21 21

21

DESCRIPTION

PROTOCOL

CLINICAL RESEARCH

Thymosin is a hormone secreted from the thymus. Its primary function is to stimulate the production of T cells, which are an important partof the immune system. Thymosin also assists in the development of B cells to plasma cells to produce antibodies. The predominant form of Thymosin, Thymosin Beta 4, is a member of a highly conserved family of actin monomer-sequestering proteins. In addition to its role as amajor actin-sequestering molecule, Thymosin Beta 4 plays a role in tissue repair. Tß4 has been found to play an important role in protection, regeneration and remodeling of injured or damaged tissues. The gene for Tß4 has also been found to be one of the fi rst to be upregulated after injuries. Thymosin Beta 4 is currently being trialed as a potential therapy for HIV, AIDS, and Infl uenza. Thymosin Beta 4 is most often prescribed for acute injury, surgical repair and for senior athletes. It has most recently been shown to help regrow hair in addition to PRP.

MOLECULAR FORMULA C212H350N56O78S


SEQUENCE Ac-Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu-Lys-

Phe-Asp-Lys-Ser-Lys-Leu-Lys-LysThr-Glu-Thr-Gin-Glu-Lys-Asn-Pro-

Leu-Pro-Ser-Lys-Glu-Thy-IleGlu-Gin-Glu-Lys-Gin-Ala-Gly-Glu-Ser

CONTENT & POTENCYINJECTABLE: 3000mcg/ml subcutaneous injection provided in a 5ml vial.

SUGGESTED DOSAGEINJECTABLE: Inject 0.25ml subcutaneously daily for 20 days.

Abstract: A cDNA clone encoding human thymosin-beta 4 was isolated from a cDNA library prepared from peripheral blood leukocytes of a patient with acute lymphocytic leukemia. This clone contained the entire coding sequence of 43 amino acid residues of thymosin-beta 4 and had an initiation codon and two termination codons. The amino acid and nucleotide sequences in the coding region were well conserved between rat and human. Nine of 132 nucleotides were di� erent in the coding sequences (93% homology), but the deduced amino acid sequences were identical. No signal peptide was found in the deduced protein sequence. Human thymosin-beta 4 mRNA, approximately 830 nucleotides in length, was about 30 nucleotides larger than rat thymosin-beta 4 mRNA. Expression of the human thymosin-beta 4 gene in various primary myeloid and lymphoid malignant cells and in a few human hemopoietic cell lines was studied. Northern blot analyses of di� erent neoplastic B lymphocytes revealed that steady state levels of thymosin-beta 4 mRNA varid as a function of di� erentiation stage. Thymosin-beta 4 mRNA levels were decreased in myeloma cells as are class II human leukocyte antigen, Fc receptor, and complement receptor, suggesting a relationship between thymosin-beta 4 and the immune response. Thymosin-beta 4 mRNA was more highly expressed in mature granulocytes than in immature blastic cells. Treatment of THP-1 cells, a human monocytic cell line, with recombinant human interferon-lambda reduced the levels of thymosin-beta 4 mRNA. Its level decreased after di� erentiation of THP-1 cells into Ia+ macrophages, but increased after di� erentiation of HL-60 cells into Ia- macrophages. The pattern of thymosin-beta 4 gene expression suggests that it may play a fundamentalrole in the host defense mechanism.

Dorr RT, Lines R, Levine N, Brooks C, Xiang L, Hruby VJ, Hadley ME. Source: College of Medicine, Pharmacology Department, University of Arizona, Tucson, USA.

DESCRIPTIONThymosin is a hormone secreted from the thymus. Its primary function is to stimulate the production of T cells,

DESCRIPTION



THYMOSIN BETA-4THYMOSIN BETA-4 IMMUNE ENHANCER

22

PT-141N A S A L S P R AY

BENEFITSWHAT IS PT-141?

SIDE EFFECTS

TYPICAL PRESCRIBING PROTOCOL:MALE & FEMALE:

• Improves female sexual arousal disorder

• Improves sexual disfunction in men (such as erectile dysfunction or impotence)

• Nausea • Flushing • Headache

• Male or Female patients may begin with intranasal administration of 2mg (1 spray in each nostril) 30 minutes prior to sexual activity.

• The dose may be titrated up to 4mg (2 sprays in each nostril) as tolerated or desired.

PT-141 was developed from the peptide Melanotan 2, which is a synthetically produced variant of a peptide hormone endogenously synthesized in the body that stimulates melanogenesis that is known as alpha- Melanocyte stimulating hormone. PT-141 has been shown in studies to provide libido-enhancing e� ects by activating the melanocortin receptors MC1R and MC4R, without tanning the skin.PT-141 is an FDA approved therapy for the treatment of female hypoactive sexual desire disorder. Studies have shown that PT-141 does not act on the vascular system and exhibits a clinically signifi cant increase in sexual desire.


REFERENCE: SHADIACK, AM, ET AL. “MELANOCORTINS IN THE TREATMENT OF MALE AND FEMALE SEXUAL DYSFUNCTION.” CURRENT TOPICS IN MEDICINAL CHEMISTRY (2007) 7: 1137. HTTP://WWW.EUREKASELECT.COM/78412/ARTICLE



Patient benefi ts include:

Side e� ects for males and females may include:

“The claims and statements have been evaluated as well as accepted by the FDA.”

23

The dose may be titrated up to 4mg (2 sprays in each nostril) as tolerated or desired.

23 SEXUAL WELLNESS PROGRAM FOR WOMENP H Y S I C I A N I N F O R M A T I O N

ADDRESSING SEXUAL WELLNESS NEEDS

ADDRESSING SEXUAL WELLNESS NEEDS

• A gel of sildenafi l/arginine, with or without menthol, may be benefi cial when applied 15-30 minutes before sexual activity to support improved libido. The body converts L-arginine into nitric oxide. Increased nitric oxide causes blood vessels to open wider for improved blood fl ow.

• A rapid dissolve tablet of oxytocin can serve as a mood booster or enhancer as well.

• A gel containing Vitamin E, DHEA and Hyaluronic Acid serves as a natural lubricant to ease potential discomfort during sexual activity and may enhance sex drive, and promote collagen formation.

Women may face a variety of challenges when it comes to sexual wellness ranging from poor lubrication and low libido to vaginal tissue health issues or painful intercourse. These issues can stand in the way of an active, healthy sex life. Through Wells Pharmacy Sexual Wellness Program, you can support your female patients in overcoming these obstacles with a variety of preparations to address their needs.

Program kits contain complementary medications made with prescription grade ingredients and do not contain controlled substances. No hormones are added since many women are receiving hormone treatment already.

Issues such as low libido or painful intercourse no longer have to stand in the way of women having an active and enjoyable sex life. Wells Pharmacy Network’s Sexual Wellness Program enables you to prescribe the formulations women need for improved sexual health and activity.


For questions about the Wells Sexual Wellness Program contact your Sales Representative.



Kits are available in 90-day supplies and to the extend permitted pursuant to a valid

prescription.

Ordering can be done through your

Sales Representative


24

SEXUAL WELLNESS PROGRAM FOR MENP H Y S I C I A N I N F O R M A T I O N

ENHANCING SEXUAL WELLNESS

PROMOTING SEXUAL WELLNESS IN MEN

• Rapid dissolve tablets that combine oxytocin with tadalafi l can be taken daily to help maintain muscle response and blood fl ow for more satisfying erections in those with erectile dysfunction. It is also used and helps with males that have BPH.

• An injectable trimix (papaverine/phentolamine/alprostadil) may be tested fi rst in the o� ce to fi nd the appropriate dosage and provide injection training. Injections twice a week can help to activate muscle response and blood fl ow.

• Arginine and Citrulline capsules may help boost Nitric Oxide and promote blood fl ood within the body.

• Rapid dissolve tablets of oxytocin alone can be prescribed as a sexual enhancer to support more satisfactory sexual wellness.

Erectile dysfunction and low sex drive or libido

are issues that many men face when it comes to

their sexual health. These problems can not only be

frustrating, but put a strain on relationships. With

Wells Pharmacy Sexual Wellness Program, you can

provide patients with a variety of preparations

to increase sexual enhancement, reduce erectile

dysfunction, and improve sex drive.

Oral medications are recommended fi rst, and if

these do not produce desired results, there are

injectable medications available as well.

To address erectile dysfunction and sexual enhancement, program kits o� er several options:

With the right combination of medications, men can enjoy an active sex life at virtually any age. Wells Pharmacy Network’s Sexual Wellness Program enables you to prescribe the medications men need for improved sexual health and activity with options for refi ll every 90 days, or as necessary and to the extent permitted pursuant to a valid prescription. For questions about the Wells Sexual Wellness Program contact your Sales Representative.


For questions about the Wells Sexual Wellness Program contact your Sales Representative.




25

25

THYMOSIN A1

ZINCVitamin D

Vitamin B Complex + Vitamin C

by Wells Pharmacy Network

by Wells Pharmacy Network

STUDIES HAVE SHOWN THAT THYMOSIN A1:• Regulates immune system response• Modulates anti-viral cytokine production• Promotes T-cell maturation and di� erentiation• Upregulates MHC Class 1 expression• Inhibits viral replication

ZINC HAS BEEN SHOWN TO:• Support the proliferation of immune cells• Decrease the incidence and duration of infections• Reduce infl ammation• Reduce in total mortality of elderly subjects by 27%

B-COMPLEX HAS BEEN SHOWN TO:• Aid the body’s ability to prevent infections• Promotes cellular health and growth of red blood cells• Be a key component in the development and maintenance of a healthy immune system

VITAMIN C HAS BEEN SHOWN TO:• Benefi t the “cytokine storm” response• A� ect the development and maturation of T-lymphocytes � Including NK (natural Killer) cells involved in the immune response to viral agents• Reduces oxidatives stress• Inhibits systemic infl ammation

VITAMIN D REPORTED CLINICAL EFFECTS:• Demonstrated reduction in viral replication rates• Decrease in infl ammatory response• Reduction in illness severity

800-622-4510 [email protected] wellsrx.com800-622-4510 [email protected] wellsrx.comIMMUNEQUAD

This package includes:• One sterile vial of Thymosin A1 at 3000 mcg/mL provided in a 5 mL vial for subcutaneous injection • 30 mL vial of B-Complex containing B2, B3, B6, B12 as Cyanocobalamin, (2 mg / 20 mg / 2mg / 300 mcg) and Vitamin C (20 mg) / mL• Zinc 30 mg (as Zinc Picolinate) 30 capsules • Vitamin D3 2000 iu (as Cholecalciferol), 30 capsules

OptimizeYour Immune System

There has never been a better time to optimize your immune system. With that in mind, the pharmacists of Wells Pharmacy Network are launching Quad Immune. As the name suggest, Quad Immune consists of four products carefully selected by pharmacist from Wells’ formulary for their clinically demonstrated e� ects on the immune system. Quad Immune’s combination of synergistic products allows for your immune system to function at its optimal state aiding in fi ghting and resisting the underlying cause of infections.

TA1

Z

D

B+C

PRODUCT CATALOGWELLS PHARMACY NETWORK

2020


Documents

2020 PRODUCT CATALOGsemax sermorelin thymosin alpha 1 thymosin beta-4 pt-141 nasal spray (eros love spray) sexual wellness program for women sexual wellness program for men quad immune